Auxilium Pharmaceuticals, Inc.: Auxilium Submits Biologics License Application for XIAFLEX(TM) for the Treatment of Dupuytren's Contracture to the U.S. Food and Drug Administration

MALVERN, PA (MARKET WIRE) Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for XIAFLEX(TM) (clostridial collagenase for injection), a novel, first-in-class, orphan-designated biologic for the treatment of Dupuytren's contracture. (Source: Market Wire - Pharmaceuticals and Biotech)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Read More... [Source: MedWorm: Dupuytren's Contracture - Posted by FreeAutoBlogger]